A new depression treatment targets the immune system instead of the brain
A treatment approach for major depressive disorder (MDD) that targets the immune system rather than brain neurotransmitters was reported to reduce symptoms in patients resistant to conventional antidepressants. According to Science Daily reporting, the results of the multi-centre clinical trial form part of a body of scientific literature in recent months strengthening the role of immune and inflammation factors in the neurobiology of depression.
Conventional antidepressant treatment focuses on regulating brain neurotransmitter balance using drugs such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). However, around one third of patients do not respond adequately to these therapies — a condition known as treatment-resistant depression (TRD). The search for alternative approaches for these patients has intensified in recent years.
The current study evaluated the effect of a biological treatment targeting specific immune-system molecules in patients with treatment-resistant depression. The trial protocol involved standard-dose administration of an antibody-based therapy with a six-week follow-up; a placebo group was used for comparison. The primary outcome measure was the change in score on the Hamilton Depression Rating Scale (HDRS).
According to the study results, around 30 per cent of patients receiving the immune therapy showed a clinically meaningful decline in HDRS scores; this was a statistically significant difference compared with the placebo group. The side-effect profile showed a relatively different spectrum compared with conventional antidepressants; the most frequently reported side effects were mild infection symptoms and injection-site reactions.
The relationship between depression and the immune system has been debated in the scientific community since the 1990s. Early studies showed that pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) were found at elevated levels in patients with major depression. However, the direction of the causal relationship — whether depression causes inflammation, or inflammation causes depression — remained uncertain for a long time.
This study shows that it is possible to alleviate depression symptoms through immune modulation; however, the study includes several important limitations. First, the sample size is relatively small; second, the long-term durability of the effect is not clear; third, a biomarker-based patient-selection strategy to predict which patients can benefit from the treatment has not yet matured.
The head of the research team conducting the study, in comments to Science Daily, said the results were 'conceptually important'. 'Treatment-resistant depression is a condition that seriously affects quality of life for millions of patients. Showing that an immune-based approach is possible sets a direction for additional research,' he said. He also stressed that the results require further validation for broad clinical use.
In the assessment of independent experts, the study's strengths — particularly its randomised, placebo-controlled design and multi-centre features — were highlighted; however, it was noted that limitations must also be taken into account. As a critical note, it was stated that the long-term use of immune-modulating therapies and their effects on immune-system health require more detailed investigation.
In terms of clinical practice, this approach is not expected to enter widespread use in the near future. Phase 3 randomised controlled trials needed for regulatory approval must be completed and efficacy validated in broader patient populations. At the same time, cost-effectiveness analyses and insurance-coverage debates will shape real-world accessibility of the treatment.
This article does not provide medical advice for depression or other mental-health conditions. Patients with depressive symptoms, or those who feel their current treatment is ineffective, should consult psychiatry specialists for a treatment plan adapted to their personal situation. Decisions about stopping or changing treatment must be taken under professional medical supervision. Clinical-trial results are preliminary and require further validation before wider clinical use.